For the quarter ended March 2025, Royalty Pharma (RPRX) reported revenue of $839 million, up 17% over the same period last year. EPS came in at $1.06, compared to $0.98 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $793.58 million, representing a surprise of +5.72%. The company delivered an EPS surprise of +7.07%, with the consensus EPS estimate being $0.99.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street ...

Royalty Pharma (RPRX) Q1 2025 Earnings Call May 08, 2025 08:30 AM ET Company Participants George Grofik - SVP & Head, IR & CommunicationsPablo Legorreta - Founder, Chairman of the Board & CEOMarshall Urist - Executive VP and Head of Research & InvestmentsTerrance Coyne - Executive VP & CFOChristopher Hite - Vice Chairman & Executive VPMichael Nedelcovych - Director - Equity ResearchGeoff Meacham - Managing Director Conference Call Participants Hardik Parikh - Equity Research AnalystTerence Flynn - Equity Re ...

Royalty Pharma (RPRX) came out with quarterly earnings of $1.06 per share, beating the Zacks Consensus Estimate of $0.99 per share. This compares to earnings of $0.98 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 7.07%. A quarter ago, it was expected that this company would post earnings of $1.09 per share when it actually produced earnings of $1.15, delivering a surprise of 5.50%.Over the last four quarters, the company has ...

Royalty Pharma (RPRX) Q1 2025 Earnings Call May 08, 2025 08:30 AM ET Speaker0 Ladies and gentlemen, thank you for standing by. Welcome to the Royalty Pharma First Quarter Earnings Conference Call. I would now like to turn the call over to George Grofic, Senior Vice President and Head of Investor Relations and Communications. Please go ahead, sir. Speaker1 Good morning and good afternoon to everyone on the call. Thank you for joining us to review Royalty Pharma's first quarter twenty twenty five results. You ...

3 Royalty Pharma plc Q1 2025 Financial Results May 8, 2025 2 Forward Looking Statements & Non-GAAP Measures This presentation has been prepared by Royalty Pharma plc (the "Company"), is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities. The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this presentation unless s ...

Portfolio Receipts growth of 17% to $839 million; Royalty Receipts growth of 12%Net cash provided by operating activities of $596 millionRaised full year 2025 guidance: Portfolio Receipts expected to be $2,975 to $3,125 million NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the first quarter of 2025 and raised full year 2025 guidance for Portfolio Receipts. “Our business momentum continued in the first quarter of 2025 as we delivered double- ...

Wall Street analysts expect Royalty Pharma (RPRX) to post quarterly earnings of $0.99 per share in its upcoming report, which indicates a year-over-year increase of 1%. Revenues are expected to be $793.58 million, up 10.7% from the year-ago quarter.Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.Prior to a company's earnings release, i ...

NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the second quarter of 2025 of $0.22 per Class A ordinary share. The dividend will be paid on June 10, 2025, to shareholders of record at the close of business on May 16, 2025. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collabor ...

NEW YORK, April 17, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its first quarter 2025 financial results on Thursday, May 8, 2025 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:30 a.m. Eastern Time that day. Conference Call Information Please visit the “Investors” page of the company’s website at https://www.royaltypharma.com/investors/events/ to obtain conference call information and to view th ...

NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Vlad Coric, M.D. to the company’s Board of Directors, effective immediately. Vlad Coric is the Chairman and Chief Executive Officer of Biohaven, a biopharmaceutical company focused on the discovery, development and commercialization of life-changing treatments in key therapeutic areas including neuroscience, immunology and oncology. “I am excited to announce that we are strengthening our Board w ...